PIA
SRNE

Piedmont Investment Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Piedmont Investment Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,509
Closed -$11K – 2514
2018
Q2 		$11K Buy
+1,509
New +$10.3K ﹤0.01% 1814

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Piedmont Investment Advisors's SRNE Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2018, closing a stake of 1,509 shares — an estimated $11K sold.

Piedmont Investment Advisors first reported a position in SRNE in Q2 2018 and held it in 1 quarter. The position peaked at $11K in Q2 2018. 97 funds tracked by Wall St. Rank hold SRNE as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 1,509 Sorrento Therapeutics, Inc. shares in Q3 2018, an estimated $11K.
  • Piedmont Investment Advisors first reported a position in Sorrento Therapeutics, Inc. in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Sorrento Therapeutics, Inc. position peaked at $11K in Q2 2018.
  • 97 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.